Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.
Non Small Cell Lung Cancer
DRUG: RAD001|DRUG: erlotinib
Phase 1: Dose limiting toxicities (DLT) and PK drug-drug interaction (DDI) measured during first 28 days of combined treatment for each treatment regimen and dose., first 28 days of combined treatment|Phase 2: Tumor response assessed by CT scans measured at baseline and after 8 weeks of treatment for each feasible dose/regimen determined in phase 1, at baseline and after 8 weeks of treatment
Phase 1: Tumor response assessed by CT scans measured at baseline, monthly until month 4 then q2months until progression, at baseline, monthly until month 4 then q2months until progression|Phase 2: Safety and steady state drug levels evaluated monthly, Monthly|Phase 1 and 2: Exploratory Biomarker assessment from archival tumor tissue, Dec 2009
This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.